GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CeriBell Inc (NAS:CBLL) » Definitions » LT-Debt-to-Total-Asset

CBLL (CeriBell) LT-Debt-to-Total-Asset : 0.09 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CeriBell LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CeriBell's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.09.

CeriBell's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Dec. 2024 (0.09). It may suggest that CeriBell is progressively becoming more dependent on debt to grow their business.


CeriBell LT-Debt-to-Total-Asset Historical Data

The historical data trend for CeriBell's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CeriBell LT-Debt-to-Total-Asset Chart

CeriBell Annual Data
Trend Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
0.18 0.03 0.09

CeriBell Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial - 0.03 0.40 0.45 0.09

CeriBell LT-Debt-to-Total-Asset Calculation

CeriBell's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=20.872/225.412
=0.09

CeriBell's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=20.872/225.412
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CeriBell  (NAS:CBLL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


CeriBell LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CeriBell's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CeriBell Business Description

Traded in Other Exchanges
N/A
Address
360 N. Pastoria Avenue, Sunnyvale, CA, USA, 94085
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.